scholarly journals A Propósito do Artigo: “O Tratamento da Esclerose Múltipla com Natalizumab: Análise de uma Coorte Hospitalar”

2014 ◽  
Vol 27 (4) ◽  
pp. 409
Author(s):  
João De Sá
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Outcome ◽  
Adverse Effects ◽  
Keywords Multiple Sclerosis ◽  
Chemically Induced ◽  
Natalizumab Treatment ◽  
Antibodies Monoclonal

Keywords: Multiple Sclerosis; Natalizumab; Treatment Outcome; Antibodies, Monoclonal, Humanized/ adverse effects; Leukoencephalopathy, Progressive Multifocal/chemically induced.

scholarly journals Multiple Sclerosis Treatment with Natalizumab: Analysis of a Hospital-Based Cohort

2014 ◽  
Vol 27 (4) ◽  
pp. 437 ◽  
Author(s):  
Ana Teresa Carvalho ◽  
Pedro Abreu ◽  
Maria José Sá
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Effects ◽  
Daily Practice ◽  
Real World Data ◽  
Relapsing Remitting ◽  
Natalizumab Treatment ◽  
Post Marketing ◽  
Remitting Multiple Sclerosis ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis

<p><strong>Introduction:</strong> Natalizumab is licensed as monotherapy for relapsing–remitting multiple sclerosis. Since pivotal studies showing natalizumab efficacy, several subsequent studies confirmed the reduction in annualized relapse rate and the slowing of disability progression. Nevertheless, ‘real-world’ data, namely in Portugal, are still scarce. We intend to report demographic and clinical data of the cohort of patients treated with natalizumab in the multiple sclerosis Clinic of Centro Hospitalar São João, based on daily practice.<br /><strong>Material and Methods:</strong> We have conducted a retrospective study of multiple sclerosis patients who had been treated with natalizumab (at least one dose) from January 2007 to May 2013 in our Center. We have gathered information about demography, baseline disease, natalizumab treatment, and outcome.<br /><strong>Results:</strong> We have found 66 patients treated with natalizumab since 2007 in our center. The majority (65.2%) were female, with a mean age of 35 years, and mean disease duration of 9.5 years. Almost all patients (93.9%) had received a prior multiple sclerosis immunomodulatory therapy. Patients have been treated with natalizumab on an average time of 24 months, with a statistically significant reduction in Annualized Relapse Ratio (- 1.9, p &lt; 0.001) and Expanded Disability Status Scale score (- 0.8, p &lt; 0.001). One patient has developed progressive multifocal leukoencephalopathy; other adverse effects have been uncommon.<br /><strong>Discussion:</strong> In general, our results fit those earlier reported in other post-marketing studies. Lack of MRI data and retrospective design are the most important limitations of our study.<br /><strong>Conclusion:</strong> Our study confirms natalizumab efficacy and safety in the treatment of relapsing-remitting multiple sclerosis in a ‘realworld’ practice.<br /><strong>Keywords:</strong> Multiple Sclerosis; Natalizumab; Treatment Outcome; Antibodies, Monoclonal, Humanized/ adverse effects; Leukoencephalopathy, Progressive Multifocal/chemically induced.</p>

Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects

2012 ◽  
Vol 18 (2) ◽  
pp. 209-219 ◽  
Author(s):  
Martin S. Weber ◽  
Til Menge ◽  
Klaus Lehmann-Horn ◽  
Helena C. Kronsbein ◽  
Uwe Zettl ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Effects ◽  
Treatment Strategies ◽  
Current Treatment

scholarly journals Supplementation and therapeutic use of vitamin D in patients with multiple sclerosis: Consensus of the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology

2014 ◽  
Vol 72 (2) ◽  
pp. 152-156 ◽  
Author(s):  
Doralina Guimarães Brum ◽  
Elizabeth Regina Comini-Frota ◽  
Claúdia Cristina F. Vasconcelos ◽  
Elza Dias-Tosta
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Vitamin D ◽  
Environmental Factors ◽  
Scientific Evidence ◽  
Hypovitaminosis D ◽  
Central Nervous System Disease ◽  
Keywords Multiple Sclerosis ◽  
System Disease ◽  
Genetic And Environmental Factors

Multiple sclerosis (MS) is an inflammatory, autoimmune, demyelinating, and degenerative central nervous system disease. Even though the etiology of MS has not yet been fully elucidated, there is evidence that genetic and environmental factors interact to cause the disease. Among the main environmental factors studied, those more likely associated with MS include certain viruses, smoking, and hypovitaminosis D. This review aimed to determine whether there is evidence to recommend the use of vitamin D as monotherapy or as adjunct therapy in patients with MS. We searched PUBMED, EMBASE, COCHRANNE, and LILACS databases for studies published until September 9 th , 2013, using the keywords “multiple sclerosis”, “vitamin D”, and “clinical trial”. There is no scientific evidence up to the production of this consensus for the use of vitamin D as monotherapy for MS in clinical practice.

Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis

2018 ◽  
Vol 41 (6) ◽  
pp. 199-201 ◽  
Author(s):  
Hussein Algahtani ◽  
Bader Shirah ◽  
Hind Abobaker ◽  
Nebras Alghanaim ◽  
Fatemah Kamel
Keyword(s):  
Multiple Sclerosis ◽  
Relapsing Remitting ◽  
Natalizumab Treatment ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Natalizumab treatment in pediatric multiple sclerosis: A case report

2009 ◽  
Vol 13 (1) ◽  
pp. 67-71 ◽  
Author(s):  
Giovanna Borriello ◽  
Luca Prosperini ◽  
Anna Luchetti ◽  
Carlo Pozzilli
Keyword(s):  
Multiple Sclerosis ◽  
Case Report ◽  
Pediatric Multiple Sclerosis ◽  
Natalizumab Treatment
Sign in / Sign up

Export Citation Format

Share Document